April 18 data presented at the AACR meeting showed no basis yet to say GLP-1 drugs prevent cancer, with researchers describing the evidence as promising but inconclusive.
Several studies linked the medicines to fewer obesity-related cancers and better survival, but others found little association; one study flagged possible kidney-cancer risk, while thyroid-cancer concerns from animal work have not held up strongly in people.
2.5 years after tirzepatide won weight-loss approval, scientists say the newest and most effective drugs have not been studied long enough for a disease with long timelines like cancer.
Researchers said answers will likely require a mix of randomized trials, real-world patient data and animal studies as use expands to newer products such as the newly approved pill Foundayo.
How can we prove if these drugs prevent cancer without waiting a decade for clinical trials?
Beyond weight loss, do drugs like Ozempic truly fight cancer, or do they hide unproven risks?
Could your DNA soon predict if a weight-loss drug will lower your specific cancer risk?
GLP-1 RAs and Cancer: 2026 Evidence Review, Risk Reduction Metrics, and Future Directions
Overview
Recent research presented at the 2026 ASCO GI Symposium highlights the potential of GLP-1 Receptor Agonists (GLP-1 RAs) in cancer prevention, especially for colorectal cancer. These findings suggest a significant public health impact and open new possibilities for reducing colorectal cancer rates in various groups. Notably, GLP-1 RAs were shown to lower colorectal cancer risk in people who started the medication before age 45, and this benefit was seen regardless of obesity or diabetes status. However, the risk reduction did not apply to individuals who used tobacco or had atherosclerosis.